D. R. Barnidge, S. Dasari, C. M. Botz, D. H. Murray, M. R. Snyder et al., Using mass spectrometry to monitor monoclonal immunoglobulins in patients with a monoclonal gammopathy, Journal of Proteome Research, vol.13, pp.1419-1427, 2014.

T. Dejoie, J. Corre, H. Caillon, P. Moreau, M. Attal et al., Responses in multiple myeloma should be assigned according to serum, not urine, free light chain measurements, Leukemia, vol.33, pp.313-318, 2019.

J. Flores-montero, L. Sanoja-flores, B. Paiva, N. Puig, O. Garc-ia-s-anchez et al., Next Generation Flow for highly sensitive and standardized detection of minimal residual disease in multiple myeloma, Leukemia, vol.31, pp.2094-2103, 2017.

F. Kendrick, N. D. Evans, B. Arnulf, H. Avet-loiseau, O. Decaux et al., Analysis of a compartmental model of endogenous immunoglobulin G metabolism with application to multiple myeloma, Frontiers in Physiology, vol.8, p.149, 2017.

N. Korde, M. Roschewski, A. Zingone, M. Kwok, E. E. Manasanch et al., Treatment with carfilzomib-lenalidomide-dexamethasone with lenalidomide extension in patients with smoldering or newly diagnosed multiple myeloma, JAMA Oncology, vol.1, pp.746-754, 2015.

S. Kumar, B. Paiva, K. C. Anderson, B. Durie, O. Landgren et al., International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma, Lancet Oncology, vol.17, pp.328-346, 2016.

C. Mazzotti, L. Buisson, S. Maheo, A. Perrot, M. L. Chretien et al., Myeloma MRD by deep sequencing from circulating tumor DNA does not correlate with results obtained in the bone marrow, Blood Advances, vol.2, pp.2811-2813, 2018.
URL : https://hal.archives-ouvertes.fr/hal-01919042

J. R. Mills, D. R. Barnidge, and D. L. Murray, Detecting monoclonal immunoglobulins in human serum using mass spectrometry, Methods, vol.15, pp.56-65, 2015.

J. R. Mills, D. R. Barnidge, A. Dispenzieri, and D. L. Murray, High sensitivity blood-based M-protein detection in sCR patients with multiple myeloma, Blood Cancer Journal, vol.7, p.590, 2017.

L. M. Moore, S. Cho, and K. L. Thoren, MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins, Clinica Chimica Acta, vol.18, pp.91-94, 2019.

P. Moreau, How I treat myeloma with new agents, Blood, vol.130, pp.1507-1513, 2017.

A. Perrot, V. Lauwers-cances, J. Corre, N. Robillard, C. Hulin et al., Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma, Blood, vol.132, pp.2456-2464, 2018.
URL : https://hal.archives-ouvertes.fr/hal-02006039

M. Roshal, J. A. Flores-montero, Q. Gao, M. Koeber, J. Wardrope et al., MRD detection in multiple myeloma: comparison between MSKCC 10-color single-tube and EuroFlow 8-color 2-tube methods, Blood Advances, vol.1, pp.728-732, 2017.

L. Sepiashvili, M. C. Kohlhagen, M. R. Snyder, M. A. Willrich, J. R. Mills et al., Direct detection of monoclonal free light chains in serum by use of immunoenrichment-coupled MALDI-TOF mass spectrometry, Clinical Chemistry, vol.65, pp.1015-1022, 2019.

K. L. Thoren, Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease, Seminar Hematology, vol.55, pp.41-43, 2018.